Loading organizations...
Key people at MAN & SCIENCE.
MAN & SCIENCE was founded in 2011 by Robert Taub (Founder & chairman).
Man & Science develops advanced neuromodulation solutions specifically targeting severe headache disorders, including chronic migraine and cluster headache. The company engineers minimally invasive, battery-free neurostimulation systems designed to reduce the pain and frequency of headache attacks. Additionally, it leverages image-guided navigation technology to enable precision-targeted injections directly to implicated nerve bundles, offering a refined therapeutic approach in an outpatient setting.
The company was founded in 2011 by Robert Taub. Drawing on his prior experience in establishing medical device companies, notably Nyxoah, Taub recognized the significant unmet need for innovative and effective treatments for debilitating headache conditions. His background underscores a commitment to translating complex scientific principles into practical, patient-centric medical technologies.
Man & Science primarily serves individuals suffering from chronic, severe headaches, such as those with persistent migraine and cluster headache who seek alternatives to conventional treatments. The company's long-term vision centers on transforming the lives of these patients by continuously turning innovative ideas into reality, ultimately enabling them to achieve a normal, pain-free existence through advanced therapeutic interventions.
MAN & SCIENCE was founded in 2011 by Robert Taub (Founder & chairman).
Man & Science is a Belgian private medical device company specializing in innovative, minimally invasive therapeutic solutions for severe headache disorders, including migraine and chronic cluster headache.[1][2][3] The company develops neurostimulation systems and image-guided precision injection technologies that enable outpatient procedures to interrupt nerve signals, reducing pain frequency and severity for patients who have not responded to conventional treatments.[2][3] Its portfolio targets a massive unmet need, as migraine affects 1 in 5 women and 1 in 15 men globally, with therapies like a battery-free occipital nerve field stimulation (ONFS) system implantable in 20 minutes and precision botulinum toxin injections in 15 minutes.[1][2]
In 2022, Man & Science expanded through the acquisition of Norway's Palion Medical, adding navigated injectable therapies for chronic migraine and cluster headache, complementing its neuromodulation offerings.[1] Key milestones include FDA Breakthrough Device Designation in 2021 for its ONFS system, accelerating U.S. market access for chronic cluster headache treatment.[3] Led by CEO Fabian Suarez and Chairman Robert Taub, the company emphasizes patient-centric, outpatient-driven innovations to restore normal, pain-free lives.[1][2]
Man & Science emerged as a Belgian medtech venture focused on headache disorders, though exact founding details are not specified in available records; its public milestones trace to at least 2021 with FDA interactions and 2022's Palion Medical acquisition.[1][3] Chairman Robert Taub has been instrumental as the "architect" of strategic moves like the Palion deal, highlighting his role in shaping the company's headache-focused portfolio.[1] The team comprises experienced scientists, engineers, clinical specialists, business experts, and serial entrepreneurs, actively recruiting for R&D, clinical, and QA roles.[2]
Growth accelerated via the 2022 acquisition of Palion Medical, spun out from Norway's University of Science & Technology, which brought precision injection tech for sphenopalatine ganglion targeting in awake patients.[1] This built on Man & Science's core neuromodulation work, earning FDA Breakthrough Designation for ONFS in chronic cluster headache—a pivotal validation of its early innovations.[3]
Man & Science rides the neuromodulation wave in medtech, addressing chronic pain—a market projected to grow amid rising neurological disorder prevalence like migraine (second most disabling condition globally).[2] Timing aligns with FDA's Breakthrough program push for expedited access to devices treating debilitating headaches, where traditional drugs often fall short.[3] Favorable forces include aging populations, demand for non-opioid outpatient therapies, and advances in image-guided navigation, positioning the company to disrupt a segment reliant on invasive implants or systemic meds.[1][2]
By consolidating assets like Palion, it influences the ecosystem through portfolio synergies, potentially setting standards for precision headache interventions and inspiring spinouts from academic hubs like NTNU.[1] This strengthens Europe's medtech footprint in U.S. markets via FDA priority review.
Man & Science is poised for U.S. commercialization of its ONFS system post-FDA Breakthrough, with Palion tech enabling broader migraine/cluster indications and pipeline expansions like injectable neurostimulation.[1][3] Trends like AI-enhanced navigation and non-invasive pain tech will amplify its edge, while partnerships or further M&A could scale global reach. Its influence may evolve from niche innovator to headache therapy leader, delivering outsized impact for underserved patients—turning innovative ideas into pain-free realities as promised.[2]
Key people at MAN & SCIENCE.
